Find and Pitch Jounalists, Get Your Story Covered

Tags: gear reviews gaming shopping video games

	Profile	Recent Articles on Subject
1	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Biotechs emerging from stealth take aim at pharma’s prime targets - 23 days ago Teva targets schizophrenia to build on innovative medicines growth - about 2 months ago After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum? - 7 months ago Astellas’ science chief on the leap into new technologies - about 1 year ago
2	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	BridgeBio Oncology to Go Public in SPAC Deal Bringing $450M+ for Trio of Cancer Drugs - about 2 months ago Vertex Pharma Challenger Sionna Secures $191M in IPO Cash for Cystic Fibrosis Pipeline - 2 months ago Takeda Pays $200M for Keros Therapeutics Drug With Potential in Blood Cancers and Beyond - 4 months ago Cancer Biotech Repare Therapeutics Restructures to Focus on Clinical-Stage Pipeline - 8 months ago J.P. Morgan Leads $100M Financing for Startup’s R&D of Covalent Biologic Drugs for Cancer - 12 months ago Another ADC Developer Lands a Mega Round of Financing for Cancer Clinical Trials - about 1 year ago J&J-Partnered Contineum Corrals $110M From IPO for Clinical Trials in Fibrosis & MS - about 1 year ago
3	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments - 2 months ago Merck is broadening its pipeline as Keytruda’s patent cliff looms - 3 months ago Autobahn’s road to a breakthrough depression treatment is paved with high-profile investors - 8 months ago In a Duchenne market beset by problems, Capricor data marks a bright spot - 8 months ago Kyverna follows oncology’s CAR-T cell playbook for an ultra-rare autoimmune disorder - 9 months ago Black Diamond looks to outwit cancer mutations - about 1 year ago
4	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Rab Prinjha - 5 months ago Simon Jones - 7 months ago
5	Michael Gibney Pharma Voice Teacher of English. Teacher of politics. Santiago, Chile educationpolitics	An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond - 5 months ago Their Alzheimer’s treatment worked — but shares fell anyway - 8 months ago 23andMe inches closes to cancer immunotherapy, guided by its genetic database - 8 months ago Now a biopharma powerhouse, Vertex’s R&D bedrock could deliver tomorrow’s blockbusters - 12 months ago
6	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about ballooning 340B drug sales, Catalent reassuring customers, and more - 6 months ago STAT+: Pharmalittle: We’re reading about weight loss drugs, a cell therapy for melanoma, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about a lawsuit against J&J, Express Scripts dealings, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about Novo buying Catalent, Amgen’s obesity drug, and more - about 1 year ago STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud - over 1 year ago STAT+: Pharmalittle: Curevac loses key patent in battle with BioNTech; Abernethy to step down as Verily CMO - over 1 year ago STAT+: Pharmalittle: Employers hire virtual providers as obesity drug gatekeepers; Vertex non-opioid nerve pain drug succeeds in mid-stage trial - over 1 year ago STAT+: Pharmalittle: Bluebird’s sickle-cell screwups may prompt a sale; drugmakers raised prices on widely used meds without new clinical evidence - over 1 year ago STAT+: Pharmalittle: Biden pharma patent proposal spurs fears; Klobuchar questions company behind price spike of lead poisoning antidote - over 1 year ago STAT+: Vertex may face another battle in the U.K. over the value of its cystic fibrosis medicines - over 1 year ago STAT+: Pharmalittle: Sarepta Duchenne therapy misses primary endpoint; FDA holds panel for first CRISPR treatment for sickle cell - over 1 year ago
7	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	STAT+: Pharmalittle: We’re reading about a soft-tissue cancer drug approval, the Zepbound shortage ending, and more - 9 months ago STAT+: Vertex non-opioid drug reduces chronic nerve pain in mid-stage study - over 1 year ago STAT+: Inside Vertex’s decades-long quest to develop a new class of non-opioid painkillers - over 1 year ago
8	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Biotech led by J&J veterans launches with $165 million for cancer, autoimmune therapies - 9 months ago STAT+: Cardiovascular startup raises $260 million led by ex-Moderna execs’ new VC fund - 9 months ago STAT+: Investors funnel $275 million into Paragon Therapeutics spinout - about 1 year ago STAT+: Biotech FogPharma raises $145 million in anticipation of more clinical trials, pharma partnerships - about 1 year ago STAT+: Biotech launches with $135 million for Vertex-competing pain medicine - about 1 year ago STAT+: A Q&A with Vertex founder Joshua Boger on Casgevy, the biotech industry, and Elon Musk - over 1 year ago STAT+: Biotech incubator Curie.Bio graduates its first startup - over 1 year ago
9	Elie Dolgin Nature Science journalist. Writes for eliedolgin.com. Somerville, Massachusetts science journalism	A Trojan horse for thirsty tumours - 9 months ago
10	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Pharmalittle: We’re watching a Cytokinetics deal with Royalty Pharma, Cue Health shutting down, and more - 11 months ago STAT+: This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act - about 1 year ago

Journalists covering Curve Therapeutics